Cerus Corporation reported $76M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $76M (to Q4 2018). Net income: −$6.8M, trailing twelve months to Q2 2026. Free cash flow: −$1.8M, trailing twelve months to Q2 2026. EPS: −$0.03, trailing twelve months to Q2 2026.

CERSCerus Corporation

Healthcare

$2.27+42% 1Y

$2.27

$1.4052 weeks$3.29

CERS as reported

Cerus Corporation reported $76M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$76M

Revenue, trailing twelve months · to Q4 2018 · every figure below is as filed, with no scoring applied

Net income: −$6.8M
Net income · −64% year on year · trailing twelve months to Q2 2026
Free cash flow: −$1.8M
Free cash flow · −153% year on year · trailing twelve months to Q2 2026
EPS: −$0.03
EPS · −70% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CERS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$76M	n/a	Q4 2018 · 30 quarters behind
Net income	−$6.8M	−64%	Q2 2026
EPS	−$0.03	−70%	Q2 2026
Gross margin	54%	n/a	Q4 2018 · 30 quarters behind
Operating margin	−79%	n/a	Q4 2018 · 30 quarters behind
Net margin	−83%	n/a	Q4 2018 · 30 quarters behind
ROE	−19%	n/a	Q2 2026
ROA	−5.5%	n/a	Q2 2026
ROIC	−4.2%	n/a	Q2 2026
Free cash flow	−$1.8M	−153%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.